FDA Approves Anktiva for BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer

FRIDAY, April 26, 2024-- The U.S. Food and Drug Administration has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive, non-muscle invasive...